TD Cowen Reiterates Buy Rating on Halozyme Therapeutics (HALO)
Tweet Send to a Friend
TD Cowen analyst Brendan Smith reiterated a Buy rating and $65.00 price target on Halozyme Therapeutics (NASDAQ: HALO).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
